Please ensure Javascript is enabled for purposes of website accessibility

Reopening Stocks Have Soared in 2021 -- but Is All the Good News Priced In?

By Matthew Frankel, CFP® and Toby Bordelon - Jun 26, 2021 at 8:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's why some of the best-performing stocks of 2021 could have more upside ahead.

Stocks in industries that are best positioned to benefit from the economic reopening have soared recently, and for good reason. Ever since positive vaccine data showed a light at the end of the tunnel of the pandemic, stocks of retailers, hotels, airlines, and other companies that depend on people getting out and doing things have been some of the market's best performers. In this Fool Live video clip, recorded on June 14, contributors Matt Frankel, CFP, and Toby Bordelon discuss whether there could be more upside ahead or if all the good news is already priced in.

Toby Bordelon: "Do you think reopening stocks are already priced in for summer growth?" There is an argument to be made they are I think. I think that's something you definitely have to look at. I think one thing we tried to do with these nine companies we presented, it's to think a little bit beyond just the immediate summer, too. I don't want to necessarily speak for you guys, but I think for me, when I was thinking of this, I was looking at the summer as potential short-term catalysts. But I wanted the company I wanted to be able to see that it could continue to perform into the fall, into next year, into the year after. You don't want to be looking at a company where you think it's going to be great this summer and then it's going to fall off a cliff. You want one that maybe will get jump-started, one that's been struggling the past year. But you see some opportunity for continued growth beyond just the short-term travel surge, for instance. I think that's what you want to think about when you're looking at investing in some of these companies. You got to see beyond the next three to six months before you want to commit your capital to it.

Matt Frankel: One thing I would point out with that is that over the last eight or nine months or so, every aspect essentially of the reopening has surprised to the positive. From Pfizer's (PFE -0.72%) vaccine data in November, which was better than anyone thought it was going to be, to the actual pace of the vaccine rollout, to the actual collapse of the case numbers this year, to the actual loosening of restrictions. No one thought New York City will be fully reopened this summer, if you asked them six months ago. The reopening has really progressed and surprised to the upside. That could easily continue to happen. Just from going out and seeing like when I was in Orlando about a month ago. The demand, the actual crowds, and things like that, I think it could continue to surprise to the upside. Yes, what we know right now might be priced in, but the market's been wrong over the past nine months about how quickly the reopening was going to progress.

Matthew Frankel, CFP has no position in any of the stocks mentioned. Toby Bordelon has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$49.75 (-0.72%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.